Microglia contribute to pathophysiology at all stages of multiple sclerosis. Colony-stimulating factor-1 (CSF1) is crucial for microglial proliferation and activation. In this study we measured the CSF1 levels and studied its cellular expression in the mouse spinal cords with experimental autoimmune encephalomyelitis (EAE) to explore the potential contribution of CSF1 in neuronal death. ELISA data showed that CSF1 levels were significantly higher in the spinal cords with acute and chronic EAE than those of normal and adjuvant-injected mice. Immunohistochemical studies demonstrated that CSF1 was expressed in astrocytes and neurons in normal mouse spinal cord. In acute EAE, CSF1 expression was significantly increased, especially in astrocytes in peripheral white matter and large motoneurons. High density of activated microglia was observed in the gray matter where motoneurons expressed high-level CSF1 in acute EAE. Significant large motoneuron loss was seen in chronic EAE and the remaining motoneurons with high-level CSF1 were enwrapped by microglia. Viral vector mediated over-expression of CSF1 in spinal neurons induced profound proliferation and activation of microglia at the injection site and microglia enwrapped CSF1-transduced neurons and their neurites. Significant loss of large CSF1-transduced neurons was seen at 2 and 3 weeks post-viral injection. Demyelination in the CSF1-transduced areas was also significant. These results implicate that CSF1 upregulation in CNS may play an important role in the proliferation and activation of microglia in EAE, contributing to neuroinflammation and neurodegeneration.
| INTRODUCTION
Multiple sclerosis (MS) is a neurological disorder characterized by progressive demyelination, resulting in progressive loss of motor and sensory functions. MS is by nature an inflammatory disease, contributed by the combined action of many types in central and peripheral immune cells (Dendrou, Fugger, & Friese, 2015) . However, the exact neuroinflammatory processes that underpin the pathophysiology of the disease are still not fully understood. It has long been postulated that a T-cell driven inflammatory response, potentially caused by peripherally activated T helper 1 (Th1) or Th17 cells that migrate to the central nervous system (CNS), initiates a chain of events that lead to progressive demyelination and axonal damage (Legroux & Arbour, 2015) . However, an expanding body of evidence has suggested that the innate immune system is also important in initiating or maintaining inflammation. Microglia, dendritic cells, natural killer cells, and mast cells have all been implicated in the pathogenesis of MS (Gandhi, Laroni, & Weiner, 2010) . In particular, the role of microglia as potentially important innate immune cells involved in the axonal and axoglial disruption seen in chronic MS, has drawn attention to the mechanisms underlying immune cell activation in the pathophysiology of the disease (Bogie, Stinissen, & Hendriks, 2014; Carson, 2002; Goldmann & Prinz, 2013) . Various factors can activate microglia including colony-stimulating factor-1 (CSF1) (Kierdorf & Prinz, 2013) .
CSF1 is a cytokine crucial for microglial proliferation, maturation, and survival during development and in adult CNS (Elmore et al., 2014; Kondo & Duncan, 2009) . CSF1 can activate the tyrosine kinase in the intracellular domain of CSF1 receptor (CSF1R), triggering an intracellular signaling pathway (Chitu, Gokhan, Nandi, Mehler, & Stanley, 2016) . Another cytokine, interleukin-34 (IL34), has also been identified as a ligand of CSF1R and is required for the development of microglia (Wang et al., 2012) .
CSF1-CSF1R signaling pathway has been reported to be responsible for the proliferation of microglia in mouse models of prion (Gomez-Nicola, Fransen, Suzzi, & Perry, 2013 ) and Alzheimer's diseases , and amyotrophic lateral sclerosis (Martínez-Muriana et al., 2016) . The involvement of CSF1 in the pathogenesis of MS has also been implicated in previous studies. In a rat MS model, experimental autoimmune encephalomyelitis (EAE), CSF1 mRNA levels in the spinal cords detected by Northern blot increased significantly before the onset of early clinical signs and peaked before maximal clinical incidence of disease (Hulkower et al., 1993) . Recently, it was reported that CSF1 immunoreactivity in the spinal cords in the early pre-symptomatic phase of rat EAE model was increased (Borjini, Fernandez, Giardino, & Calza, 2016) .
These data indicate that CSF1 upregulation may contribute to the initiation of neuroinflammation in EAE. However, there is no detailed study on the actual levels of CSF1 and IL34 proteins and the cellular expression of CSF1 proteins in the CNS of EAE mice at both acute and chronic stages. Our laboratory has developed an EAE model in Biozzi ABH mice that closely mimics the relapsing-remitting and secondary progressive MS (Al-Izki et al., 2012) . Using this animal model, we measured the CSF1 and IL34 levels in the plasma and in the spinal cords, the main site of pathology of EAE mice. We also identified the cell types that express and upregulate CSF1 in acute and chronic EAE, and explored the potential relationship between activated microglia and the death of CSF1-expressing neurons. Furthermore, we examined the effects of viral vector mediated overexpression of CSF1 in spinal neurons on the proliferation and activation of microglia and the loss of the CSF1-transduced neurons.
| MATERIALS AND METHODS

| Induction of EAE in mice and sample collection
Experiments were performed in accordance with the United Kingdom Animals (Scientific Procedures) Act 1986, following local ethical review of procedures. Acute and chronic mouse EAE models were induced according to the method used routinely in our laboratory (AlIzki et al., 2012; Baker et al., 1990; Pryce et al., 2005) . Biozzi ABH mice (both male and female, 8 weeks old) bred in our Biological Service Unit were used. Briefly, spinal cord homogenate emulsified with complete Freunds adjuvant (incomplete Freund's adjuvant supplemented with both Mycobacterium tuberculosis and M. butyricum) was injected subcutaneously in both hindflanks and again 7 days later.
Mice were monitored during the relapsing-remitting phase of disease progression, as previously documented.
For measurement of CSF1 and IL34 by ELISA, acute EAE mouse spinal cord samples were obtained by sacrificing animals with clinical score 4 (complete hind limb paralysis for 2 days) via CO 2 asphyxiation at days 17-18 after first inoculation. Blood was obtained by severing cardiac vessels and collected in EDTA-coated tubes which were centrifuged to extract plasma. The spinal cords were ejected using hydrostatic pressure applied to the spinal column via a 20 gauge needle. All samples were frozen immediately by immersion in liquid nitrogen and stored at −80 C. Chronic EAE mice were sacrificed after the development of the secondary progressive phase of disease, between days 60-90 postinduction. Spinal cords and plasma were obtained using the same procedures as described above. Spinal cords and plasma were also obtained from mice 17 days after the first complete adjuvant injection, serving as controls, in addition to normal mice.
For immunohistochemistry, animals were sacrificed at the same time points as described above. After deep anesthesia, mice were transcardially perfused with saline followed with 4% paraformaldehyde. Spinal cords were dissected and postfixed in 4% paraformaldehyde for 1 day, then transferred to 30% sucrose in PBS for 1 day.
Spinal cords were then cut into three segments and embedded in OCT compound and stored at −80 C until required.
| ELISA
Spinal cord samples from normal, adjuvant-injected, acute and chronic EAE mice were weighed and then minced using a pair of small scissors. Extraction buffer composed of 0.04% bovine serum albumin and complete™ protease inhibitors (Roche Diagnostics, Burgess Hill, UK)
in PBS (pH 7.4) was added to each sample at 5 μl per mg of sample.
Tissues were homogenized by sonication on ice using a Vibra-Cell sonicator (Sonics and Materials, Newtown, CT) at 30W for 3 × 1 min.
Homogenates were centrifuged at 10,000g for 20 min at 4 C. Supernatants were collected and used immediately for ELISA. Concentrations of mouse CSF1 and IL34 in the spinal cords and plasma were measured using the Quantikine® Colorimetric Sandwich ELISA kits (R&D Systems, Abingdon, UK) according to the manufacturer's protocols.
| Production of lentiviral vectors
Mouse CSF1 cDNA was purchased from InvivoGen (San Diego, CA, USA). For easy identification of CSF1-transduced cells, GFP cDNA was fused in frame to CSF1 cDNA with a 2A sequence (from footand-mouth disease virus) in-between, which allows separation of CSF1 and GFP proteins during translation by a mechanism called ribosome skipping. To make the lentiviral vector (LV) expressing CSF1-2A-GFP under the control of a neuronal specific promotor, human synapsin-1 promoter (hSyn), overlap extension PCR was used to fuse CSF1 cDNA with the 2A sequence and GFP cDNA. The fused construct was then subcloned into LV transfer vector pRRL/hSyn.
LV/hSyn_CSF1-2A-GFP and the control vector, LV/hSyn_GFP, were produced based on the protocol of Dull et al. (1998) 
| Immunoblotting
To detect the secreted CSF1 in the conditioned medium, pRRL/ hSyn_CSF1-2A-GFP was transfected into HEK293 cells cultured in serum-free medium (Animal-Free PeproGrow AF-CHO Media, PeproTech EC, London, UK). pRRL/hSyn_GFP was also transfected as control. Two days after transfection, media were harvested, and concentrated by 20 times using Amicon Ultra-15 Centrifugal Filter Units (Ultracel-10K, Millipore UK, Watford, UK). Transfected cells were washed off from the culture dish with cold PBS and spun down.
Cell pellet was lysed using 400 μL Cell Lysis Buffer (10 mM Tris-HCl, 1 mM EDTA, 0.3% NP-40, complete™ proteinase inhibitors (Roche)) and centrifuged at 13,000g for 5 min at 4 C. Supernatant was transferred to another tube and stored at −80 C until required.
Conditioned media or cell lysates (9 μL each) were mixed with reducing loading buffer, heated at 70 C for 10 min, and loaded into a 4-12% SDS-PAGE precast gel (Expedeon, Cambridge, UK). Proteins were transferred to PVDF membrane, which was incubated in blocking buffer for 1 h (10% skimmed milk in TBST buffer (Tris buffered saline + 0.3% Tween 20). Membrane was then incubated with goat anti-murine CSF1 antibody (PeproTech, 1:1000 dilution in blocking buffer) overnight. After being washed in TBST for 3 × 10 min, membrane was incubated with donkey anti-goat IgG-HRP (Santa Cruz, 1:10,000 dilution in TBST). Lumigen ECL Ultra (Lumigen, Southfield, MI) was used for signal generation and ECL signal was recorded with
ChemiDoc™ XRS + System (BioRad Laboratories, Watford, UK).
| Intraspinal viral vector injection
Intraspinal injection was carried out similarly to a previously published procedure (Peluffo et al., 2013) . Thirty-six adult male Biozzi ABH mice A group of six mice was culled at 1, 2, or 3 weeks after viral vector injection and processed as described above. Lumbar spinal cords containing injection sites were removed, postfixed, and preserved in 30% sucrose before being embedded in OCT compound for sectioning.
| Immunohistochemistry
Horizontal cryostat sections (16 μm thick) of spinal cords from normal and adjuvant-injected mice, and mice with acute EAE and chronic EAE were cut, mounted onto SuperFrost Plus glass slides, and dried at room temperature for 30 min. Sections were either used immediately or stored at −20 C. Most of the spinal cord sections were doubleimmunostained for CSF1 (goat-antimouse CSF1) and a cellular marker for myelin, astrocytes, neurons, or microglia using rabbit antibodies (see Table 1 for a list of primary antibodies used) and the immuno- To verify the specificity of the goat anti-mouse CSF1 antibody from PeproTech, another goat anti-mouse CSF1 antibody from R&D Systems (Table 1) which has been used for immunostaining CSF1 in DRG and spinal motoneurons (Guan et al., 2016) , was tested on our spinal cord sections. Both antibodies stained neurons and astrocytes with similar pattern of immunoreactivity (data not shown).
To detect the expression of CSF1 and GFP in spinal neurons in LV/hSyn_CSF1-2A-GFP injected spinal cord, double immunostaining for CSF1 and GFP was performed on cross sections (16 μm thick) using a goat anti-mCSF1 and a rabbit anti-GFP antibodies (see Table 1 ). For labeling LV/hSyn_CSF1-2A-GFP or LV/hSyn_GFP transduced neurons and microglia, sections were double immunostained using a rabbit anti-GFP and a goat anti-Iba1 antibody. processed with a maximum intensity projection tool to create a final image with pixels containing the maximum value at the whole stack.
| Quantification and statistical analysis
In order to quantify the increased expression of CSF1 in spinal neurons and neuronal loss in acute and chronic EAE mice, horizontal sec- the six mice, the average level was significantly higher than the normal and the adjuvant-injected mice, but not significantly different from the acute EAE mice ( Figure 1a ). The CSF1 level in normal mouse plasma was 722 ± 153 pg/mL, which was similar to that observed in the spinal cord of normal mice ( Figure 1a ). CSF1 level in acute EAE mouse plasma was significantly lower than that in normal mice, but not significantly different from the chronic EAE mice ( Figure 1a ). Interestingly, CSF1 level in the plasma of the adjuvant-injected mice was significantly higher than all the other three groups.
IL34 level in normal mouse spinal cord was 7690 ± 1054 pg/g wet tissue ( Figure 1b ) and adjuvant injection did not significantly change the IL34 level in the spinal cord. In the spinal cords of both acute and chronic EAE mice, IL34 levels were also not significantly different from the normal and adjuvant-injected mice. In chronic EAE mice IL34 levels in individual mice also varied significantly (Figure 1b) . The IL34 levels in the plasma were much lower than in the spinal cords and they were at the lower limit for detection with the ELISA kit used. with chronic EAE, some areas in the peripheral white matter displayed strong CSF1 immunoreactivity (marked by asterisks in Figure 2m ), but weak MAG-immunoreactivity (marked by asterisks in Figure 2n ), indicating demyelination in these areas. The cells with strong CSF1 immunoreactivity in these areas resembled reactive astrocytes, which was confirmed by the immunostaining for GFAP (see Section 3.3).
3.3 | CSF1 expression in astrocytes in the white matter increases significantly in acute and chronic EAE mice (pointed by white arrows in Figure 3d ). In the spinal cord of acute EAE mice, GFAP expression increased in the astrocytes, especially those in the peripheral regions of the white matter, indicating the activation of astrocytes. The reactive astrocytic processes were much thicker and longer (hypertrophy) and CSF1 levels in these reactive astrocytes and their processes were significantly higher (pointed by the white arrowheads in Figure 3h ). In the spinal cord of chronic EAE, patches in the peripheral white matter showed high-level CSF1 expression ( Figure 3i ) which overlapped with the high-level GFAP immunoreactivity, reflecting the presence of astrogliosis in these areas (Figure 3j ).
Higher density of cells was also shown in these areas as demonstrated by the nuclear staining (Figure 3k) . Quantification of the intensities of CSF1 immunoreactivity in the white matter confirmed that CSF1 was significantly upregulated in both acute and chronic EAE spinal cords (Figure 3m ).
3.4 | CSF1 expression in astrocytes in the gray matter does not increase significantly in acute and chronic EAE mice
Marked increase in the number of astrocytes was observed in the gray matter of acute and chronic EAE spinal cords (Figure 4f,j) . However, no Figure 6 ). In the chronic EAE mice, the number of large motoneurons was significantly lower than those in normal and acute EAE spinal cords, and also the number of large neurons with high-level CSF1 was much lower. This may implicate that large motoneurons with high-level CSF1 had died during the progression of EAE to the chronic stage.
3.6 | High-level CSF1 expression in white matter correlates with high density of microglia in acute and chronic EAE spinal cords Double immunostaining for CSF1 and a microglial marker Iba1 showed that in the white matter of normal spinal cord, microglia were predominantly ramified and in "resting" state ( Figure 7b ). In the acute EAE spinal cord, a large number of amoeboid microglia were seen (Figure 7f ), indicating they were activated. In the peripheral white matter where astrocytes expressed high-level of CSF1 (pointed by a yellow arrow in Figure 7e ) a high density of Iba1 + cells were adjacently present (pointed by a green arrow in Figure 7f ). In the peripheral region of the white matter of chronic EAE mouse spinal cord, high-level CSF1 expression (indicated by yellow arrows in Figure 7i ) also correlated with a high-density of Iba1 + cells (indicated by green arrow in Figure 7j ). These observations indicate that high-level CSF1 expression promotes local proliferation or migration of microglia. However, the regions with high-density of Iba1 + cells may also contain a population of infiltrating macrophages as it was reported by Ajami, Bennett, Krieger, McNagny, and Rossi (2011). Figure S2 ).
| Lentiviral construct mediates co-expression of CSF1 and GFP in vitro and in vivo
HEK293 cells were able to express the CSF1-2A-GFP construct after transfection even though a neuron-specific synapsin-1 promoter was used. CSF1 immunoreactivity was found to be mainly located on the membrane while GFP accumulated in the nuclei (Figure 10a Clusters of Iba1 + cells were seen in the CSF1-GFP transduced areas, which were more prominent 2 week postinjection (marked by * in Figure 11r ). Those Iba1 + cells in clusters were not macrophages penetrated into the parenchyma of spinal cord as these cells were also positive for a new microglia-specific marker, TMEM119 (Bennett et al., 2016) , confirming that they were indeed microglia (Supporting Information Figure 3S ).
| Overexpression of CSF1 in spinal neurons leads to the loss of large transduced neurons
We noticed that there were fewer large CSF1-GFP-transduced neurons in ventral horn (presumably motoneurons) at 2 and 3 weeks postinjection than that at 1 week ( Figure 11m ,q,u), therefore, we counted the GFP + large neurons in both LV/hSyn_GFP and LV/hSyn_CSF1-2A-GFP injected groups. In LV/hSyn_GFP injected group, there was no difference in the number of large GFP + neurons at 1, 2, and 3 weeks, however, in LV/hSyn_CSF1-2A-GFP injected group the numbers of large GFP + neurons were significantly lower than that at 1 week (Figure 13 ), suggesting that CSF1
induced proliferation and activation of microglia seen in Figure 11 led to the loss of the large neurons.
| Overexpression of CSF1 in spinal neurons causes demyelination of CSF1-expressing neurons
To examine whether the proliferation and activation of microglia induced by overexpressed CSF1 led to demyelination as microglia were closely associated with CSF1 + neurites (Figure 12h,l) , the myelin levels in the spinal sections immunostained with MAG were studied. As expected, there was no obvious difference in the levels of MAG immunoreactivity in the GFP-transduced and untransduced areas (Figure 14b ). However, there was noticeable reduced level of MAG immunoreactivity in the CSF1-GFP transduced areas (marked by * in Figure 14f ) compared with the adjacent untransduced areas. The level of MAG immunoreactivity in CSF1-GFP transduced area was 46% lower than that in the adjacent untransduced area (Figure 14i ). We further examined the sections using confocal microscopy and found that the GFP + large axons (about 5 μm in diameter) of GFP transduced neurons were smooth and myelinated as GFP and MAG immunoreactivities were closely associated (pointed by white arrows in Figure 14l,o) . However, the CSF1-GFP + axons showed limited association with MAG immunoreactivity (Figure 14r,u) .
| DISCUSSION
In this study, we showed that CSF1 levels were markedly elevated in acute EAE mouse spinal cord. The elevated CSF1 levels in acute EAE spinal cords were similar within the treatment group, which may reflect the uniformity of the onset of the initial attack in the mice after induction (Al-Izki et al., 2012) . The CSF1 levels in chronic EAE mouse spinal cords were also elevated, however, the levels varied significantly within the group, which may be due to the big variation in severity of neurodegeneration in individual mice at chronic stage of disease (Al-Izki et al., 2012) . Our results on elevated CSF1 protein levels in spinal cords agree with a study on mRNA levels in rat spinal cords with acute EAE (Hulkower et al., 1993) . By measuring the densities of the mRNA bands in Northern blots CSF1 mRNA levels in rat spinal cords was shown to increase 8 days after induction and reached peak levels on day 12, the height of clinical symptoms. Using a colony stimulating assay as an indirect measurement for the levels of CSF1 , 2016) . In a peripheral nerve injury model, CSF1 mRNA levels in dorsal root ganglia (DRG) and spinal cords increased significantly while IL34 mRNA levels did not change (Okubo et al., 2016) .
However, in a prion disease model, using in situ hybridization, it was shown that CSF1, IL34, and CSF1R mRNAs increased in the hippocampus and thalamus (Gomez-Nicola et al., 2013) . These results imply that IL34 may respond differently in different pathological conditions.
In our study, CSF1 concentrations in blood plasma decreased in acute EAE mice, but the reduction was not significant in chronic EAE mice, indicating that the elevated CSF1 in the spinal cords of EAE mice was produced in situ. In a recent study, it was reported that CSF1 concentration in rat plasma increased one day after EAE induction, but then continued decreasing into the initial acute attack (Borjini et al., 2016) . The mechanism underlying such change of plasma CSF1 remains to be determined. CSF1 level in plasma of the adjuvant-injected mice was significantly higher than that of normal mice, which may reflect the peripheral inflammation induced by adjuvant. It is also higher than the mice with chronic EAE, which may be explained by that adjuvant-induced inflammation had subsided 60-90 days postinduction. However, a reason for the lower CSF1 level in plasma in acute EAE mice in comparison with the normal and the adjuvant-injected mice remains unclear.
The increased expression of CSF1 in the acute and chronic EAE mouse spinal cord was supported by immunohistochemical studies. (Calvo, Dobbertin, Gelman, Glowinski, & Mallat, 1998; Frei, Nohava, Malipiero, Schwerdel, & Fontana, 1992; . Astrocytes associated with pia mater expressed a higher level of CSF1 than those inside the spinal cord parenchyma. In acute EAE mice, astrocytes were activated, especially in the peripheral region of the white matter, and CSF1 expression was markedly increased in these reactive astrocytes.
A base-level expression of CSF1 is essential for maintaining a stable pool of microglia in the CNS of normal mice. However, increased CSF1 expression in the peripheral white matter also correlated with higher density of Iba1 + cells in the same regions, where major pathological changes occur in EAE. We postulate that the increased expression and secretion of CSF1 in those astrocytes stimulate proliferation and activation of microglia, which may release inflammatory factors and participate in the demyelination process. Astrocytes have been regarded as an important player in various CNS pathological conditions including MS and they may actively participate in both lesion development and repair (Correale & Farez, 2015) . Recently it was reported that a type of neurotoxic reactive astrocytes were induced by activated microglia, which results in the death of neurons and oligodendrocytes (Liddelow et al., 2017) . Therefore, microglia and astrocytes can interact with each other and exuberate demyelination and neurodegeneration.
Large motoneurons in the spinal cords also significantly increased the expression of CSF1 in acute and chronic EAE, which may be responsible for increased proliferation and activation of microglia in the gray matter. Neuronal loss was not so obvious in the acute stage, but significant loss of large motoneurons was observed in the chronic stage. Since many large motoneurons with high-level CSF1 expression were encircled by microglia in the spinal cords from both acute and chronic EAE mice, we presume that neuronal loss may be partly due to the action of microglia. A study on a mouse ALS model supports However, some studies suggest that CSF1-CSF1R signaling pathway is neuroprotective. Luo et al. showed that administration of CSF1 or IL34 prevented the loss of pyramidal neurons and microgliosis in mouse hippocampus after kainic acid injection (Luo et al., 2013) . Furthermore, they also found that systemic administration of CSF1 ameliorated memory deficits in a transgenic mouse model of Alzheimer's disease, which contradicts the findings from other research groups (Dagher et al., 2015; Olmos-Alonso et al., 2016; Spangenberg et al., 2016) . In another hippocampal lesion model using induced expression of diphtheria toxin A-chain, Rice et al. found that eliminating microglia using PLX3397 improved functional outcomes after lesioning, but potentiated neuronal loss during lesion formation (Rice et al., 2015) . In a brain ischemia model, Jin et al. reported that depletion of microglia by blocking CSF1R using PLX3397 exacerbated neurological deficits and brain infarction . However, Li et al. (2017) reported that eliminating microglia with PLX3397 attenuated brain injury after intracerebral hemorrhage. Although cytotoxicity of microglia has been recognized for a long time (Banati, Gehrmann, Schubert, & Kreutzberg, 1993) , latest studies indicate that microglia may exert different effects in different types of lesions and at different stages of the lesions. It is generally recognized that microglia exist in different phenotypes with different functions (Boche, Perry, & Nicoll, 2013 ) and whether they are neuroprotective or neurotoxic may depend on the pathological conditions and/or age of the brain and spinal cord (Biber, Owens, & Boddeke, 2014) .
We also observed that microglia were in close contact with CSF1 + axons, which raises the possibility that those microglia might also damage the axons and cause demyelination. Clusters of activated microglia were observed in the white matter of brain from MS patients (Singh et al., 2013; van Horssen et al., 2012) . However, it is unknown whether those clusters were induced by local increase of CSF1. Microglia nodules were reported to be associated with degenerating axons (Singh et al., 2013) . We did find that in the peripheral It has been known that microglia activated by inflammation can phagocytose stressed but viable neurons, resulting in neuronal death by phagoptosis, cell death caused by phagocytosis of the cells (Brown & Neher, 2014 ). An in vitro experiment showed that CSF1 stimulated phagocytic activity of adult human microglia (Smith et al., 2013) . It was previously observed that injury to a peripheral nerve led to proliferation and hypertrophy of microglia around the axotomized motoneurons and in the central projection territories of the peripherally axotomized sensory neurons, where they phagocytosed degenerating axons and terminals (Svensson et al., 1993) . Recently the signal molecule for such microglial reaction to peripheral nerve injury was identified as CSF1 (Guan et al., 2016) . Increased secretion of CSF1 may act as an injury signal and elicit inflammatory reaction, therefore, we postulate that in EAE immune attack on CNS myelin triggers the upregulation of CSF1 and induces the proliferation, activation, and phagocytosis of microglia, which in turn, damage and phagocytose the stressed neurons and the axons.
In order to confirm that increased CSF1 does act as an injury signal, we expressed CSF1 in spinal neurons to mimic the increased expression of CSF1 in these neurons in EAE mice. Indeed, over- In summary, we have found that CSF1 was significantly upregulated in the spinal cords of both acute and chronic EAE mice.
Astrocytes and neurons were identified as the main source of CSF1, which led proliferation and activation the microglia. Activated microglia were closely associated with CSF1-expressing neurons and astrocytes, and may be responsible for neuronal loss and demyelination at the chronic stage of EAE. Engineered overexpression of CSF1 in spinal neurons also led to the loss of large neurons and demyelination, mirroring what was observed in EAE spinal cords. The findings from this study support for a role of CSF1 in the pathogenesis and progression of EAE, and potentially MS, and CSF1-CSF1R signaling pathway may be a potential target for development of treatments to slow or halt the neurodegeneration in progressive MS.
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